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Abstract 
 
Aims: The aim of the study was to examine the temporal associations between substance 
use and sub-clinical psychosis symptoms. Design: Data from a prospective community study 
sampled within a single cohort over 30 years (1978-2008) were analyzed with discrete-time 
hazard models. Setting: General population based sample. Participants: At initial sampling 
in 1978 males (N=292) were 19 and females (N=299) were 20 years old. Measurements: 
Two psychosis syndromes representing “schizotypal signs” and “schizophrenia nuclear 
symptoms” and various substance use variables including cannabis, alcohol, tobacco and 
multiple-drug use (i.e. cannabis combined with other drugs). Findings: In bivariate analyses, 
alcohol (OR=1.48, 95%-CI=1.05-2.09), tobacco (OR=1.76, 95%-CI=1.09-2.82), and cannabis 
(OR=2.29, 95%-CI=1.32-3.97) were associated with schizotypal signs. Schizophrenia 
nuclear symptoms were related to alcohol (OR=1.84, 95%-CI=1.00-3.38), cannabis 
(OR=1.59, 95%-CI=1.03-2.46), and multiple-drug use (OR=2.35, 95%-CI=1.38-4.02). 
Multivariate analyses showed that in particular regular cannabis use during adolescence was 
associated with the occurrence of subsequent schizotypal symptoms over a 30-year period 
(OR=2.60, 95%-CI=1.59-4.23), whereas multiple-drug use in adolescence was 
predominantly associated with schizophrenia nuclear symptoms (OR=1.75, 95%-CI=1.01-
3.03). Alcohol misuse was only slightly associated with the onset of such symptoms. 
Conclusions: A significant portion of the occurrence of subclinical psychosis symptoms in 
adulthood can be attributed to excessive cannabis and multiple-drug use during 
adolescence. This is in line with the hypothesis that long-term sensitization of dopaminergic 
brain receptors plays a role in developing psychotic symptoms. 
Keywords: substance abuse, cannabis, alcohol, sub-clinical psychosis, psychotic 
experiences, schizophrenia, epidemiology 
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Introduction 
 
Dopamine disregulation is a central component in the pathogenesis of schizophrenia [1-3]. 
Heightened dopaminergic neurotransmission likely leads to an aberrant assignment of 
salience to normal stimuli as a precursor of full blown psychosis [4]. The capacity to increase 
dopamine levels in the central nervous system also is a common feature of all substances 
with addictive potential, including cocaine, amphetamine, alcohol, opioids, nicotine, and 
cannabis [5]. The use of these substances, alone or in combination, is widespread among 
adolescents and can provoke psychotic symptoms [6]. Notably several studies have found a 
positive association between cannabis use and psychosis [7-11]. For reviews see [12,13]. To 
our knowledge, however, no research within a prospective, longitudinal community sample 
has focused on temporal associations between different patterns of substance use and the 
subsequent occurrence of sub-clinical psychosis symptoms. Therefore, our objective was to 
examine the age-related effects of multiple substance use as they apply to the development 
of sub-clinical symptoms over a 30-year period.  
 
 
Method 
Sample 
 
The sampling method for the Zurich Study was based on a two-phase procedure described 
by Dunn et al [14]. Fairly common in epidemiological research, it is characterized by both 
screening and interviews. The latter is carried out with a subsample of initially screened 
subjects, and is typically stratified along selected criteria and cut-offs. In statistical analysis, 
those stratified data must be weighted to receive correct point estimates, such as prevalence 
rates. 
In 1978, we sampled 4547 subjects (2201 males, 19 years old; 2346 females, 20 years old) 
who were considered representative of the canton of Zurich in Switzerland. Male and female 
participants were sampled with different approaches. In Switzerland every male person has 
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to undertake a military screening test at the age of 19. Therefore conscripts of a defined 
catchment area represent the respective complete male age group. With the consent of the 
military authorities but independent of their screening procedure, we randomly screened 50% 
of all male conscripts of this age group. The refusal rate was 0.3%. The female participants 
of the age 20 were identified from the complete electoral register. Again, 50% of these 
women were randomly selected and received questionnaires by mail; 75% of them 
responded. All 4547 subjects received a demographic questionnaire and the Symptom-
Checklist 90-Revised (SCL-90-R) [15]. The SCL-90-R is a comprehensive self-report 
questionnaire of 90 items, which cover a broad range of psychiatric symptoms. Because a 
lower educational level was over-represented among the non-responding women, we 
corrected that by matching the educational levels between females and males during the 
screening process.  
For the second sampling phase, we applied a stratification procedure to enrich the interview 
sample with cases at risk for the development of psychiatric syndromes. Stratification was 
based on a cut-off value of the SCL-90-R global severity index (GSI) score, which was 
obtained in the initial screening-phase as specified above. That means that two-thirds of the 
final interview sample comprised randomly drawn high scorers (defined by the 85th 
percentile or above on SCL-90-R GSI scores) from the screening-sample of 4547 subjects 
while the remaining third were randomly selected from the rest of the screening-sample (GSI 
scores below the 85th percentile). The GSI cut-off values were 1.57 and 1.89 for males and 
females, respectively. In all 591 subjects (292 males, 299 females) were chosen with this 
procedure. 
Face-to-face interviews were conducted in 1979 (participants aged 20/21), 1981 (22/23), 
1986 (27/28), 1988 (29/30), 1993 (34/35), 1999 (40/41), and 2008 (49/50). The numbers of 
participants are indicated in Figure 1. The different assessments waves were conducted 
within 1 to 1.5 years. Over the entire time span of 30 years, 57% of the original interview-
sample continued to participate. Those who dropped out did not differ significantly in their 
demographics from those subjects who remained in the study. The initial allocation to the two 
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groups split through the cut-off of the 85th percentile of the GSI has not changed over the 
time span, although drop-outs were rather extremely high or low scorers on the GSI [16]. 
 
(Insert Figure 1 here) 
 
Instruments 
 
Interviews were conducted according to the “Structured Psychopathological Interview and 
Rating of the Social Consequences of Psychological Disturbances for Epidemiology” (SPIKE) 
[17]. This semi-structured interview, developed for epidemiological surveys in psychiatric 
research, assesses data about socio-demography, psychopathology, substance use, 
medication, health services use, impairment, and social activity. Its reliability and validity 
have been reported previously [18]. Clinical diagnoses of psychotic disorders could not be 
assessed with the SPIKE because the required criteria were not included in the interviews 
from 1979 up to 1999. For the interview from 2008 an additional chapter on psychosis was 
included in the SPIKE. This section allowed us to provide a 12-month diagnosis of broad 
psychosis, which is based on DSM-IV criteria for schizophrenia. According to that algorithm 
no participant fulfilled the criteria for a DSM-IV psychosis.  
In addition to the information from the SPIKE, we also used the SCL-90-R during all 
assessment waves, in which subjects responded according to a five-point Likert scale of 
distress that ranged from “not at all” (1) to “a little bit” (2), “moderately” (3), “quite a bit” (4), 
and “extremely” (5). The SCL-90-R covered the most recent four-week period 
psychopathology for each time of measurement. Its 90 items are grouped along nine 
subscales that reflect a broad spectrum of symptoms. We applied two SCL-90-R subscales 
relevant to psychosis (“paranoid ideation” and “psychoticism”). According to the SCL-90-R 
manual, six items within the former subscale, as originally designed, characterize projective 
thoughts, hostility, suspicion, grandiosity, centrality, fear of losing autonomy, and delusions. 
The latter subscale (10 items) includes terms indicative of a socially withdrawn, isolated, 
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schizoid lifestyle, as well as those that represent symptoms of psychosis and schizophrenia, 
e.g., hallucinations and thought-broadcasting.  
 
Measures 
 
The SCL-90-R has historically shown good internal consistency and test–retest reliability 
[19,20]. However, the factor structure of that instrument has led to contradictory results. 
Commonly, fewer than nine factors are identified [20], and the “psychoticism” subscale yields 
the least consistent data [21]. Such discrepancies have been reported since the very first 
stages of developing this questionnaire [15].  
Because of these inconsistencies, we used factor analysis with the PROC FACTOR 
procedure of SAS (V8.2/Windows) and Promax rotation to challenge those “paranoid 
ideation” and “psychoticism” subscales. Our repeated waves of assessment over 30 years 
allowed us to replicate and, thus, validate the factor structure. All analyses were confined to 
those two subscales. Items that consistently loaded jointly on the same factor over six waves 
were then selected for building two new subscales. These steps led to a slight 
rearrangement of respective items from the original subscales (Table 1). Our first new 
subscale matched the original paranoid ideation subscale but added the items “feeling lonely 
even when with people”, and “never feeling close to another person” from the original 
“psychoticism” subscale. This subscale was used to address social and interpersonal 
deficiencies with reduced capacity for close relationships as well as ideas of reference, odd 
beliefs, and suspicion/paranoid ideation. As such, this factor was reminiscent of criteria 
required for diagnosing a “schizotypal personality disorder”. Thus we named this new 
subscale “schizotypal signs”.  
Our second new subscale included the items of thought insertion, thought-broadcasting, 
thought control, and hearing voices, all from the original “psychoticism” subscale. These 
represent attenuated forms of the nuclear symptoms of schizophrenia. We named this the 
“schizophrenia nuclear symptoms” subscale. For that, three items on the original 
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“psychoticism” subscale were eliminated while two others were shifted to the new 
“schizotypal signs” subscale. We have previously detailed the construction of those two 
psychosis dimensions [22]. Our rearranged subscales have now been applied in various 
other studies [23-25] and have also been confirmed recently through a principal component 
analysis for a population of about 5000 participants in the Netherlands [26]. Hence, we 
conclude that our revised and independently verified SCL-90-R subscale structure presents 
psychosis symptoms in that questionnaire in a more adequate and stable manner. 
 
(Insert Table 1 here) 
 
Because some statistical procedures required dichotomous variables (see below), we 
defined the occurrence of psychotic symptoms as scoring at least as high as the 85th 
percentile on each psychosis subscale. Single or occasional psychotic symptoms that arise 
without functional impairment are quite prevalent in the general population, with prevalence 
rates between 10% and 15% [22,27]. Therefore, we chose that cut-off to include preferably 
pronounced but sub-threshold symptoms in our analysis. The dichotomous psychotic 
symptom variables assessed retrospectively the four-week prevalence rate of those 
symptoms at all interview waves, i.e. in 1979, 1981, 1986, 1988, 1993, 1999, and 2008.  
Participants were classified as adolescents up to 19/20 years old and as adults from 19/20 to 
49/50. Substance use was grouped according to the recorded information concerning 
substance use during adolescence versus adulthood. The exception was for multiple-drug 
use, which was only evaluated for the category of youngest participants. Because the 
screening was conducted at age 19/20 (in the year 1978), the assessment of substance use 
up to that age was necessarily retrospective. The following interviews always encompassed 
the last twelve months prior to the respective interview. To assess substance use up to the 
age 19/20, participants were asked to indicate how frequently they used a given substance if 
ever used up to that age. In all subsequent interviews participants were asked if they had 
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used a given substance during the previous twelve months. All information about substance 
use was assessed with the SPIKE. The variables considered for substance use included:  
• For cannabis: no use; casual (up to three times per month); or regular (once per week 
up to daily). 
• For frequency of alcohol intoxication in adolescence: no intoxication; casual (having 1 
to 10 intoxications until age 19/20); or regular (having 11 and more intoxications until age 
19/20). 
• For alcohol misuse in adulthood: yes vs. no (according to DSM-III, III-R, and IV 
criteria for alcohol abuse and/or dependence). 
• For frequency of alcohol use in adulthood: once per week or less vs. several times 
per week. 
• For onset of tobacco use: adolescence (up to the age of 19/20) vs. adulthood (after 
age 19/20). 
• For magnitude of tobacco use: less than 20 cigarettes and none vs. 20 cigarettes and 
more. 
• For multiple-drug use during adolescence: yes vs. no (multiple-drug use comprises 
cannabis and at least one other substance, e.g., LSD, mescaline, speed, or other 
amphetamines). 
 
For adjustment of the associations between substance use and psychotic symptoms we 
used the following covariates: sex, familial background (raised by no biological parent, one 
parent, or both parents; or adopted), socio-economic status (i.e., parents’ income), family 
history of mental disorders, other family problems (i.e., harsh punishments, neglect, or 
conflicts with parents), and school problems (i.e., conflicts with teachers and peers, bullying, 
or performance pressure). All covariates were assessed with the SPIKE. Family and school 
problems were assessed in the interviews from 1986 and 1988, respectively. All other 
variables were provided in the first interview in 1979. 
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Statistical analyses 
 
Post-hoc power analyses were carried out with G*Power 3 [28] using a two-tailed test and 
α=0.05. Power was estimated for samples sizes N=591 and N=335, respectively. 
Associations between substance use and psychotic symptoms were evaluated with discrete-
time hazard models, i.e., via survival analyses. Information was arranged into a longitudinal 
person–period data set, in which an individual had multiple records for every repeated 
measure. The total number of records in the response categories of a given substance use 
variable is indicated in Tables 2-5. Each entry for an individual was configured as a new 
record, defining each event occurrence as a dichotomous variable for every year of the data 
assessment (i.e., a target event occurred or did not occur at follow-up). The recording of 
further events stopped after a subject had experienced the target event, which was defined 
as having happened when a subject first scored at least as high as the 85th percentile on our 
newly defined psychosis subscales. This we also referred to as the occurrence of 
“schizotypal signs” or “schizophrenia nuclear symptoms”. For example, if a subject first 
reported such defined symptoms higher or equal the 85th percentile at the third interview 
wave, three data entries in every psychosis subscale were recorded for him or her, i.e. one 
for each completed interview (i.e., 1979, 1981, and 1986). Censoring occurred when a 
subject either definitively dropped out of the cohort or never experienced the target event 
after all follow-ups.  
Discrete-time hazard models rely on binary logistic regressions with longitudinal data. Their 
statistical framework has been described by Singer and Willett [29]. Initially, we conducted 
series of bivariate analyses of substance use and psychotic symptoms for separate 
substance-use variables. Each was adjusted for sex, familial background, socio-economic 
status, family history of mental disorders, other family problems, and school problems. In 
contrast, for multivariate analyses, all variables were entered simultaneously, using a forward 
step-wise (likelihood ratio) method. In the multivariate models we included all such variables 
that had shown significant associations in our bivariate analyses. The models adjusted each 
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variable for all others. To avoid biased results through multi-collinearity we excluded 
predictor variables that were intercorrelated greater than 0.5. Intercorrelation of the predictor 
variables was analyzed with Spearman coefficients.  
All statistical analyses were conducted with SPSS version 17 for Macintosh. 
 
 
Results 
Power analyses 
 
Post-hoc power analyses revealed that for a binomial predictor variable with an OR=2.0 the 
statistical power (1-β error probability) was reduced from 0.92 for N=591 to 0.69 for N=335. 
For an OR=1.8 the power was reduced from 0.80 for N=591 to 0.54 for N=335. Those two 
odds ratio estimates correspond to a moderate effect size. 
 
Bivariate analyses 
 
The bivariate analyses showed that scores ranking equal to or higher than the 85th percentile 
on the “schizotypal signs” subscale were significantly associated with the use of cannabis, 
alcohol, and tobacco (Table 2). Altogether, 5 out of 8 substance-use variables were 
significantly associated with high scores on the “schizotypal signs” subscale over the 30 
years assessed. The strongest associations were found for casual (OR=1.80, 95%-CI=1.22-
2.66, p=0.003) and regular (OR=2.29, 95%-CI=1.32-3.97, p=0.003) cannabis use in 
adolescence. The cumulative survival rate over time for cannabis use in adolescence is 
shown in Figure 2. The graph illustrates the occurrence of schizotypal signs over time in 
association with early cannabis use and demonstrates a clear dose-response relationship. 
 
(Insert Figure 2 here) 
(Insert Table 2 here) 
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The bivariate associations for the subscale of “schizophrenia nuclear symptoms” were 
slightly weaker than those for the first subscale (Table 3), with only 3 of 8 substance-use 
variables being significantly associated with the occurrence of such symptoms. Furthermore, 
tobacco use was not significantly correlated. The strongest associations were found for 
regular alcohol intoxication in adolescence (OR=1.84, 95%-CI=1.00-3.38, p=0.049) and for 
multiple-drug use in adolescence (OR=2.35, 95%-CI=1.38-4.02, p=0.002). The cumulative 
survival rate over time for multiple-drug use in adolescence is shown in Figure 3. Further 
figures for the other substance-use variables can be provided on request. 
 
(Insert Figure 3 here) 
(Insert Table 3 here) 
 
Multivariate analyses 
 
The correlation matrix showed that there were no intercorrelations greater than 0.5 between 
the bivariate predictors of the “schizotypal signs” and therefore all variables were included in 
a multivariate model. The multivariate model of the “schizotypal signs” yielded two significant 
predictors for high scores on the “schizotypal signs” subscale (Table 4) – the frequency of 
cannabis use in adolescence (for casual use: OR=1.80, 95%-CI=1.24-2.59, p=0.002; for 
regular use: OR=2.60, 95%-CI=1.59-4.23, p<0.001) and alcohol misuse in adulthood 
(OR=1.39, 95%-CI=1.02-1.90, p=0.040). 
Intercorrelations of the bivariate predictors of the “schizophrenia nuclear symptoms” were 
also smaller than 0.5 and therefore all variables were included in the multivariate model. The 
multivariate analyses of the “schizophrenia nuclear symptoms” subscale (Table 5) revealed 
that the frequency of alcohol intoxication in adolescence (for casual intoxication: OR=1.59, 
95%-CI=1.14-2.21, p=0.006; for regular intoxication: OR=1.69, 95%-CI=0.91-3.14, p=0.099) 
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and multiple-drug use in adolescence (OR=1.75, 95%-CI=1.01-3.03, p=0.047) were 
significantly predictive of high scores on the respective psychosis scale. 
 
(Insert Table 4 here) 
(Insert Table 5 here) 
 
 
Discussion 
 
To our knowledge this is the first study linking substance use and sub-clinical psychotic 
symptoms over 30 years and within a community cohort. For most substances, those 
associations presented here were moderately but persistently positive with psychotic 
symptoms. In the bivariate analyses, all substance-use variables were adjusted for numerous 
parameters, including familial background, socio-economic status, family history of mental 
disorders and other problems, as well as conflicts met in school. Because our records on 
substance use were so detailed, we could adjust each pattern of use toward other 
substances in the multivariate analyses. This enabled us to evaluate the impact of different 
substances independently and in relation to their frequency of use as reported by the 
participants of the study.  
 
The psychosis symptoms studied here do not reach the threshold for a diagnosis of 
schizophrenia. However, considering the dimensional character of psychosis, it seems quite 
important that the occurrence of psychotic symptoms should be assessed below such a 
threshold, particularly with regard to preventive measures. 
The common denominator for all substances analyzed in this project is their potential impact 
on dopamine transmission or release. As such they can contribute to the occurrence of 
psychosis symptoms where dopaminergic disregulation plays an important role [1,2]. The 
temporal gap between the assessment of substance use in adolescence and symptoms 
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manifested during adulthood makes it unlikely that those substances have only an immediate 
or acute impact. Rather, the respective brain receptors are sensitized for a psychotic 
response in the long term [30,31].  
But we are aware that other factors might contribute as well. We ourselves found in a 
previous study [22], that cannabis use in adolescence was associated specifically with 
schizophrenia nuclear symptoms, whereas childhood adversity as well as chronic physical or 
mental disorders in parents contributed to schizotypal signs. Individuals with a persistently 
high level of either of the two identified symptom dimensions over 20 years experienced 
significant deficiencies in social achievement and functioning. Therefore we deliberately 
adjusted for a broad range of covariates in the present study. 
 
Our bivariate analyses are in accord with those reported elsewhere. For example, in healthy 
subjects, cannabis use and alcohol abuse are associated with the incidence of psychotic 
experiences [32-35]. Alcohol abuse also can induce psychotic disorders [36]. Moreover, 
empirical evidence has demonstrated that alcohol use is correlated with subsequent brain 
abnormalities and increased risk of psychosis in subjects at high genetic risk for 
schizophrenia [37]. Regular tobacco use has also been found to relate to the occurrence of 
psychotic symptoms [9,32] with the onset of the former preceding that of the latter [38,39].  
Multiple-drug use has not yet been shown to have any additional long-term influence on the 
occurrence of psychotic symptoms or schizophrenia. In bivariate analyses that followed the 
subscale of “schizophrenia nuclear symptoms”, we found considerably higher OR values for 
multiple-drug use (i.e., cannabis plus at least one other drug) compared with the use of 
cannabis alone ore no cannabis use during adolescence. In the multivariate analysis, when 
adjusting for other substances, multiple-drug use was still significantly related to 
“schizophrenia nuclear symptoms”. Substances such as LSD, mescaline, and speed can 
immediately cause psychosis-like symptoms [6]. Furthermore, they appear to have delayed 
effects on the occurrence of symptoms when cannabis is the primary factor, whereas 
cannabis use alone did not yield the same effect [31]. A recent review [40] of associations 
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between stimulants (speed or cocaine) and psychosis supports this finding. A plausible 
explanation for this could be that cannabis and other drugs interact in the dopaminergic 
system and consequently worsen the outcome.  
Finally, we also provide further evidence for the existence of a dose-response relationship, in 
that greater cannabis use during adolescence and adulthood leads to higher OR values for 
psychosis symptoms. Prospective studies of the associations between cannabis use and 
later psychosis in the general population have determined that the risk of psychotic outcomes 
is enhanced in individuals who use cannabis very frequently [7,12].  
 
Strengths and limitations 
 
We believe that our prospective evaluation is the first to examine not only several substances 
but also their patterns of use as they relate to the development of sub-clinical psychotic 
syndromes. Although its longitudinal design means that our results can contribute to 
aetiological research, our analyses do not allow us to make definitive causal conclusions. For 
many of the significant associations identified here, a causal link seems to be quite plausible. 
This is especially true for cases where substance use assessed during adolescence 
preceded the occurrence of psychosis symptoms in adulthood. In our analyses this pertained 
to cannabis, alcohol, or multiple drugs. Furthermore, our results seem to be quite robust as 
we could control for several potential confounders. By focusing on sub-threshold syndromes, 
we have presented evidence for an association that is quite common in the general 
population and which does not restrict the validity of the results only to specific or rare, high-
risk populations. Population-based studies allow researchers to investigate the association 
between substance use and incident psychotic symptoms before psychopathology becomes 
clinically relevant.  
Despite the strengths described here, this study also has some limitations. First, the sample 
size was initially small and was then further reduced by attrition. This markedly diminished 
our statistical power for predictor categories that comprised relatively few qualifying 
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participants (e.g., those who reported regular cannabis use in adulthood). Second, we could 
not derive an exact temporal order because, at each time of measurement, we recorded only 
the 12-month prevalence for substance use and a 4-week prevalence for psychotic 
symptoms. Some intervals between interview waves also were quite long, making it 
impossible for us to determine whether participants had used substances or experienced 
psychotic symptoms during those gaps that were not covered by the interviews. We were 
similarly not able to assess psychotic symptoms prior to 1979, wherefore some participants 
may have shown the symptoms in question already before they started to use substances. 
Even if so, they still reported more psychotic symptoms after the onset of substance use. 
Furthermore, as indicated in Figures 2 and 3 psychotic symptoms rather occur many years 
after the beginning of substance use. Overlooking the 30 years time interval we can state 
that in may cases there is a clear temporal order, i.e. that in many cases the occurrence of 
psychotic symptoms is preceded by substance use. Third, the information assessed and 
analyzed here relied on self-report instruments for which responses might have been biased 
by omissions or intentional concealment. Nevertheless, because all of the data collected 
were held in strict confidence, we choose to assume that most reports were reliable. If we 
imply a major bias concerning the assessment of substance use, we would preferably expect 
an underreporting of substance use, which in turn would result in a decrease and 
underestimation of the association between substance use and psychotic symptoms. 
 
In summary we believe that we could make a contribution to a more rational discussion in 
this field. Data from a prospective community study sampled within a single cohort over 30 
years demonstrate that a significant portion of the occurrence of sub-clinical psychotic 
symptoms in adulthood can be attributed to excessive cannabis and multiple-drug use during 
adolescence. In this context it is very important to understand the early phases within a 
pathogenetic process when trying to prevent the onset of a certain illness. These would 
include alcohol and cannabis, in particular, because their use is amenable to preventive 
measures. Young people should be provided with information about the risks of substance 
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use even more as sub-clinical psychotic symptoms also put a strain on one’s personal 
relationships and professional career [22].  
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Table 1: 
Items for new subscales of “schizophrenia nuclear symptoms” and “schizotypal signs” that 
replace those for the “paranoid ideation (PN) and “psychoticism” (PS) subscales from the 
original SCL-90-R. 
 
New SCL-90-R items Original SCL-90-R subscalea 
“Schizophrenia nuclear symptoms” subscale  
7: Someone else can control your thoughts PS 
16: Hearing voices other people do not hear PS 
35: Other being aware of your thoughts PS 
62: Having thoughts that are not your own PS 
“Schizotypal signs” subscale  
8: Others are to blame for your troubles PN 
18: Feeling most people cannot be trusted PN 
43: Feeling you are watched by others PN 
68: Having ideas others do not share PN 
76: Others not giving you proper credit PN 
77: Feeling lonely even when with people  PS 
83: Feeling people take advantage of you PN 
88: Never feeling close to another person PS 
 
a Items excluded from the original PS subscale are 84: Thoughts about sex that bother you a lot; 85: Idea you 
should be punished for sins; 87: Idea something is wrong with body; and 90: Idea something is wrong with your 
mind. 
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Table 2: 
Discrete-time hazard models for bivariate associations between substance use and the 
occurrence of high scores on the “schizotypal signs” subscale. Values for significant 
associations are indicated in bold.  
 
Substance-use variablesa  Occurrence of target event
  OR (95% CI) N of target 
events (%) 
Frequency of cannabis use in 
adolescence: 
None (N=1749)  
Casual (N=320)  
Regular (N=131) 
1 (Reference) 
1.80 (1.22-2.66) 
2.29 (1.32-3.97) 
144 (8.2) 
46 (14.4) 
26 (19.8 
Frequency of cannabis use in 
adulthood: 
None (N=1838) 
Casual (N=257) 
Regular (N=128) 
1 (Reference) 
1.47 (0.94-2.29) 
1.80 (1.00-3.22) 
160 (8.7) 
35 (13.6) 
22 (17.2) 
Frequency of alcohol 
intoxication in adolescence: 
No intoxication (N=901) 
Casual (N=1130) 
Regular (N=163) 
1 (Reference) 
1.48 (1.05-2.09) 
1.74 (0.96-3.16) 
65 (7.2) 
124 (11.0) 
22 (13.5) 
Alcohol misuse in adulthood: No (N=2061) 
Yes (N=162) 
1 (Reference) 
1.66 (0.92-2.98) 
197 (9.6) 
20 (12.3) 
Frequency of alcohol use in 
adulthood: 
Once per week or less (N=1584) 
Several times per week (N=622) 
1 (Reference) 
1.41 (1.01-1.99) 
140 (8.8) 
75 (12.1) 
Onset of tobacco use: Never (N=748) 
Adolescence (N=1239) 
Adulthood (N=236) 
1 (Reference) 
1.38 (0.97-1.96) 
1.05 (0.57-1.91) 
58 (7.8) 
136 (11.0) 
23 (9.7) 
Tobacco use in adulthood: Less than 20 cig./none (N=2024) 
20 cigarettes or more (N=199) 
1 (Reference) 
1.76 (1.09-2.82) 
189 (9.3) 
28 (14.1) 
Multiple-drug use in 
adolescence: 
No multiple-drug use (N=1975) 
Multiple drugs (N=160) 
1 (Reference) 
1.59 (0.93-2.71) 
174 (8.8) 
25 (15.6) 
 
a Adjusted for sex, familial background, socio-economic status, family history of mental disorder, and other 
problems with family or school. The N behind the response categories refers to the number of records.  
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Table 3: 
Discrete-time hazard models for bivariate associations between substance use and the 
occurrence of high scores on the “schizophrenia nuclear symptoms” subscale. Values for 
significant associations are indicated in bold.  
 
Substance-use variablesa  Occurrence of target event
  OR (95% CI) N of target 
events (%) 
Frequency of cannabis use in 
adolescence: 
None (N=1641)  
Casual (N=340)  
Regular (N=126) 
1 (Reference) 
1.13 (0.74-1.73) 
1.73 (0.96-3.11) 
162 (9.9) 
  37 (10.9) 
  22 (17.5) 
Frequency of cannabis use in 
adulthood: 
None (N=1755) 
Casual (N=250) 
Regular (N=121) 
1 (Reference) 
1.59 (1.03-2.46) 
1.77 (0.96-3.24) 
168 (9.6) 
  36 (14.4) 
  19 (15.7) 
Frequency of alcohol 
intoxication in adolescence: 
No intoxication (N=853) 
Casual (N=1088) 
Regular (N=153) 
1 (Reference) 
1.53 (1.08-2.17) 
1.84 (1.00-3.38) 
  68 (8.0) 
128 (11.8) 
  22 (14.4) 
Alcohol misuse in adulthood: No (N=1955) 
Yes (N=171) 
1 (Reference) 
1.53 (0.82-2.85) 
205 (10.5) 
  18 (10.5) 
Frequency of alcohol use in 
adulthood: 
Once per week or less (N=1522) 
Several times per week (N=590) 
1 (Reference) 
1.10 (0.78-1.56) 
155 (10.2) 
  68 (11.5) 
Onset of tobacco use: Never (N=703) 
Adolescence (N=1216) 
Adulthood (N=207) 
1 (Reference) 
1.29 (0.74-2.24) 
1.18 (0.83-1.69) 
  63 (9.0) 
128 (10.5) 
  32 (15.5) 
Tobacco use in adulthood: Less than 20 cig./none (N=1917) 
20 cigarettes or more (N=209) 
1 (Reference) 
1.52 (0.95-2.41) 
192 (10.0) 
  31 (14.8) 
Multiple-drug use in 
adolescence: 
No multiple-drug use (N=1876) 
Multiple drugs (N=140) 
1 (Reference) 
2.35 (1.38-4.02) 
182 (9.7) 
  25 (17.9) 
 
a Adjusted for sex, familial background, socio-economic status, family history of mental disorder, and other 
problems with family or school. The N behind the response categories refers to the number of records. 
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Table 4: 
Discrete-time hazard models for multivariate associations between substance use and high 
scores on the “schizotypal signs” subscale. Only significant predictors are shown. 
 
Substance-use variablesa  Occurrence of target event
  OR (95% CI) N of target 
events (%) 
Frequency of cannabis use in 
adolescence: 
None (N=1749)  
Casual (N=320)  
Regular (N=131) 
1 (Reference) 
1.80 (1.24-2.59) 
2.60 (1.59-4.23) 
144 (8.2) 
46 (14.4) 
26 (19.8 
Alcohol misuse in adulthood: No (N=2061) 
Yes (N=162) 
1 (Reference) 
1.39 (1.02-1.90) 
197 (9.6) 
20 (12.3) 
 
a The N behind the response categories refers to the number of records. 
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Table 5: 
Discrete-time hazard models for multivariate associations between substance use and high 
scores on the “schizophrenia nuclear symptoms” subscale. Only significant predictors are 
shown. 
 
Substance-use variablesa  Occurrence of target event
  OR (95% CI) N of target 
events (%) 
Frequency of alcohol 
intoxication in adolescence: 
No intoxication (N=853) 
Casual (N=1088) 
Regular (N=153) 
1 (Reference) 
1.59 (1.14-2.21) 
1.69 (0.91-3.14) 
  68 (8.0) 
128 (11.8) 
  22 (14.4) 
Multiple-drug use in 
adolescence: 
No multiple-drug use (N=1876) 
Multiple drugs (N=140) 
1 (Reference) 
1.75 (1.01-3.03) 
182 (9.7) 
  25 (17.9) 
 
a The N behind the response categories refers to the number of records. 
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Fig 1:  
Numbers and sex of participants over seven assessment waves. 
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Fig 2: 
Survival function for the frequency of cannabis use in adolescence and the occurrence of 
schizotypal signs. 
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Fig 3: 
Survival function for multiple-drug use in adolescence and the occurrence of schizophrenia 
nuclear symptoms. 
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Fig 3: 
Survival function for multiple-drug use in adolescence and the occurrence of schizophrenia 
nuclear symptoms. 
